EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Novavax, Inc. (NVAX): A Bull Case Theory
Novavax (NVAX): Exploring Valuation After Prolonged Share Price Weakness
Is Novavax Now a Bargain After a 94.1% Five Year Share Price Slump?
Vaccine makers fall on FDA memo, Bally's wins bid for NYC casino
Novavax (NVAX) Valuation: Assessing the Shift to Partnerships and an R&D-Focused Strategy - Simply Wall St News
Novavax call volume above normal and directionally bullish | Markets Insider
What Recent Partnership Efforts Mean for the Value of Novavax in 2025
Novavax Shifts From COVID Sales to R&D Focus While Updating 2025 Forecast
JPMorgan Chase & Co. Cuts Novavax (NASDAQ:NVAX) Price Target to $6.00 - Stock Observer
JPMorgan Chase & Co. Issues Pessimistic Forecast for Novavax (NASDAQ:NVAX) Stock Price
Novavax (NVAX): Evaluating Valuation Gaps as Shares Extend Recent Slide
JPMorgan Chase & Co. Lowers Novavax (NASDAQ:NVAX) Price Target to $6.00 - Daily Political
Analysts Set Novavax, Inc. (NASDAQ:NVAX) PT at $11.38 - Markets Daily
Investment Analysts' Weekly Ratings Changes for Novavax (NVAX) - Stock Observer
Jupiter Asset Management Ltd. Buys 582,858 Shares of Novavax, Inc. $NVAX
Novavax, Inc. (NASDAQ:NVAX) Receives Consensus Recommendation of "Hold" from Brokerages
